Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) and Estrella Immunopharma (NASDAQ:ESLA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.
Institutional & Insider Ownership
61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 7.6% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Foghorn Therapeutics and Estrella Immunopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Foghorn Therapeutics | 1 | 0 | 5 | 2 | 3.00 |
| Estrella Immunopharma | 1 | 0 | 1 | 0 | 2.00 |
Volatility and Risk
Foghorn Therapeutics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.
Earnings & Valuation
This table compares Foghorn Therapeutics and Estrella Immunopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Foghorn Therapeutics | $22.60 million | 11.61 | -$86.62 million | ($1.13) | -4.11 |
| Estrella Immunopharma | N/A | N/A | N/A | ($0.34) | -4.59 |
Estrella Immunopharma has lower revenue, but higher earnings than Foghorn Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Foghorn Therapeutics and Estrella Immunopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Foghorn Therapeutics | -294.16% | N/A | -29.62% |
| Estrella Immunopharma | N/A | -1,132.38% | -411.91% |
Summary
Foghorn Therapeutics beats Estrella Immunopharma on 9 of the 13 factors compared between the two stocks.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
About Estrella Immunopharma
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
